686 M.A. Huestis
Heishman SJ, Stitzer ML, Yingling JE (1989) Effects of tetrahydrocannabinol content on
marijuana smoking behavior, subjective reports, and performance. Pharmacol Biochem
Behav 34:173–179
Holdcroft A (1984) Pain therapy. In: Grotenhermen F, Russo E (eds) Cannabis and cannabi-
noids. Pharmacology, toxicology, and therapeutic potential. The Haworth Integrative
Healing Press, New York, pp 181–186
Huang W, Moody DE, Andrenyak DM, Smith EK, Foltz RL, Huestis MA, Newton JF (2001)
Simultaneous determination of delta-9-tetrahydrocannabinol and 11-nor-9-carboxy-
delta-9-tetrahydrocannabinol in human plasma by solid phase extraction and gas
chromatography—negativeionchemicalionization—massspectrometry.JAnalToxicol
25:531–537
Huestis MA, Cone EJ (1998a) Alternative testing matrices. In: Karch SB (ed) Drug abuse
handbook. CRC Press, Boca Raton, pp 799–857
Huestis MA, Cone EJ (1998b) Differentiating new marijuana use from residual drug excre-
tion in occasional marijuana users. J Anal Toxicol 22:445–454
Huestis MA, Cone EJ (2004) Relationship of Delta-9-tetrahydrocannabinol concentrations
in oral fluid and plasma after controlled administration of smoked cannabis. J Anal
Toxicol 28:394–399
Huestis MA, Dickerson S, Cone EJ (1992a) Can saliva THC levels be correlated to behavior?
American Academy of Forensic Sciences Annual Meeting, New Orleans, p 190
Huestis MA, Henningfield JE, Cone EJ (1992b) Blood cannabinoids. I. Absorption of THC
and formation of 11-OH-THC and THCCOOH during and after smoking marijuana.
J Anal Toxicol 16:276–282
Huestis MA, Henningfield JE, Cone EJ (1992c) Blood cannabinoids. II. Models for the predic-
tion of time of marijuana exposure from plasma concentrations of delta-9-tetrahydro-
cannabinol (THC) and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THCCOOH).
J Anal Toxicol 16:283–290
Huestis MA, Sampson AH, Holicky BJ, Henningfield JE, Cone EJ (1992d) Characterization
of the absorption phase of marijuana smoking. Clin Pharmacol Ther 52:31–41
Huestis MA, Mitchell JM, Cone EJ (1995) Detection times of marijuana metabolites in urine
by immunoassay and GC-MS. J Anal Toxicol 19:443–449
Huestis MA, Mitchell JM, Cone EJ (1996) Urinary excretion profiles of 11-nor-9-carboxy-
∆9-tetrahydrocannabinol in humans after single smoked doses of marijuana. J Anal
Toxicol 20:441–452
Hunt CA, Jones RT (1980) Tolerance and disposition of tetrahydrocannabinol in man.
J Pharmacol Exp Ther 215:35–44
Hunt CA, Jones RT, Herning RI, Bachman J (1981) Evidence that cannabidiol does not sig-
nificantly alter the pharmacokinetics of tetrahydrocannabinol in man. J Pharmacokinet
Biopharm 9:245–260
Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP, Beaune P, Menez JF (1996)
Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in
human liver microsomes. Chem Res Toxicol 9:365–373
Jehanli A, Brannan S, Moore L, Spiehler VR (2001) Blind trials of an onsite saliva drug test
for marijuana and opiates. J Forensic Sci 46:1214–1220
Joern WA (1992) Surface adsorption of the urinary marijuana carboxy metabolite: the
problem and a partial solution. J Anal Toxicol 16:401
Johansson E, Halldin MM (1989) Urinary excretion half-life of delta1-tetrahydrocannabinol-
7-oic acid in heavy marijuana users after smoking. J Anal Toxicol 13:218–223
Johansson E, Agurell S, Hollister LE, Halldin MM (1988) Prolonged apparent half-life of
delta-1-tetrahydrocannabinol in plasma of chronic marijuana users. J Pharm Pharmacol
40:374–375
Johansson E, Halldin MM, Agurell S, Hollister LE, Gillespie HK (1989a) Terminal elimina-
tion plasma half-life of delta-1-tetrahydrocannabinol (selta-1-THC) in heavy users of
marijuana. Eur J Clin Pharmacol 37:273–277